Category: hypoactive sexual desire dysfunction HSDD
AndroFeme 1 licensed for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals has obtained approval for registration of AndroFeme® 1 in the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019 — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →
TGA accepts Lawley product for evaluation in postmenopausal women with HSDD.
TGA accepts Lawley product for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019 — Lawley Pharmaceuticals Pty Ltd today announced… Continue Reading →
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal… Continue Reading →